Search Result

Results for "

α6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Aryl Hydrocarbon Receptor (3) Biochemical Assay Reagents (6) Cholinesterase (ChE) (4) DNA/RNA Synthesis (3) Drug Derivative (6) Drug Intermediate (4) Drug Metabolite (7) Endogenous Metabolite (8) ERK (2) GABA Receptor (15) Integrin (3) Isotope-Labeled Compounds (11) JNK (1) Kinesin (3) Liposome (1) LXR (1) Microtubule/Tubulin (2) nAChR (29) NKCC (5) NO Synthase (1) Nucleoside Antimetabolite/Analog (1) p38 MAPK (2) PPAR (1) Reference Standards (10) β-catenin (4)
By Research Areas:	Cancer (24) Cardiovascular Disease (8) Infection (1) Inflammation/Immunology (10) Metabolic Disease (10) Neurological Disease (40)
Oligonucleotides:	Nucleoside Analogs (1) Inosine (1) Cholesterol (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0135

Furosemide 5+ Cited Publications	NKCC GABA Receptor	Cardiovascular Disease Metabolic Disease Cancer
Furosemide is a potent and orally active inhibitor of Na ⁺/K ⁺/2Cl ^- (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide is also a GABA_A receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .

HY-10019

Varenicline 1 Publications Verification CP 526555	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10021

Varenicline Tartrate 1 Publications Verification CP 526555-18	nAChR ERK p38 MAPK	Others Neurological Disease Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-W002112

(±)-Nornicotine Nornicotine	Endogenous Metabolite Drug Metabolite nAChR β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-A0009

Galanthamine hydrobromide 10+ Cited Publications Galantamine hydrobromide	Cholinesterase (ChE) nAChR	Neurological Disease
Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-133971

Cholesterol 5α,6α-epoxide 5α,6α-Epoxycholesterol	Liposome	Others
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.

HY-120874

Darigabat PF-06372865; CVL-865	GABA Receptor	Neurological Disease
Darigabat (PF-06372865) is an orally active, α2/α3/α5 subtype-selective GABA_A positive allosteric modulator (PAM). Darigabat is a high affinity ligand at GABA_A receptors containing α1/α2/α3/α5 subunits (K_is of 2.9 nM, 21 nM, 134 nM for α2, α1 PAM, α2 PAM, respectively), with low affinity for α4/α6 subunits. Darigabat can across the blood-brain barrier (BBB). Darigabat has anxiolytic activity and has the potential for epilepsy .

HY-110208

BRD9876 1 Publications Verification	Kinesin Microtubule/Tubulin	Cancer
BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research .

HY-B0135A

Furosemide sodium 5+ Cited Publications	NKCC GABA Receptor	Cardiovascular Disease Metabolic Disease Cancer
Furosemide sodium is a potent and orally active inhibitor of Na ⁺/K ⁺/2Cl ^- (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide sodium is also a GABA_A receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .

HY-10020

Varenicline Hydrochloride CP 526555 hydrochloride	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-128671

6-Thioinosine 6TI; 6-Mercaptopurine riboside	PPAR LXR JNK NO Synthase	Metabolic Disease
6-Thioinosine (6TI) is a purine antimetabolite and an anti-adipogenic agent. 6-Thioinosine reduces the mRNA levels of PPARγ and C/EBPα and downregulates the mRNA levels of PPARγ target genes (LPL, CD36, aP2, and LXRα). 6-Thioinosine exerts its anti-adipogenic effects by downregulating PPARγ through JNK-dependent iNOS upregulation. 6-Thioinosine can be used to study adipocyte dysfunction .

HY-122247

PVZB1194	Kinesin	Cancer
PVZB1194 is a biphenyl-type inhibitor of Kinesin-5 ATPase activity that binds to the α4/α6 site of the motor domain in a nucleotide competitive manner. PVZB1194 has an IC₅₀ of 0.12 μM for KSP ATPase. PVZB1194 induces mitotic arrest with the formation of a monopolar spindle, and inhibits HeLa cells proliferatio (IC₅₀: 5.5 μM). PVZB1194 can be used in the study of tumors .

HY-160959

AN317	nAChR	Neurological Disease
AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with K_i of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP ⁺. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .

HY-B0135S

Furosemide-d5	NKCC GABA Receptor	Metabolic Disease Cancer
Furosemide-d₅ is the deuterium labeled Furosemide. Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl-?(NKCC) cotransporter, NKCC1 and NKCC2 .?Furosemide is also a GABAA?receptors antagonist and displays 100-fold selectivity for?α6-containing receptors than?α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .

HY-15831

L-838417-d9	Isotope-Labeled Compounds GABA Receptor	Neurological Disease
L-838417-d₉ is the deuterium labeled L-838417 (HY-W009009). L-838417 is a selective partial agonist at the α2, α3 and α5 subtypes of the GABA_A receptor and an antagonist at the α1, with binding K_i values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2 and α6β3γ2. L-838417 has anti-anxiety activity .

HY-123349

5α-Hydroxy-6-keto cholesterol	Drug Metabolite	Cardiovascular Disease
5α-Hydroxy-6-keto cholesterol is major metabolite of β-epoxide (5α,6β-epoxycholesterol) during direct exposure of intact cultured human bronchial epithelial cells (16-HBE) to ozone. 5α-Hydroxy-6-keto cholesterol inhibits cholesterol synthesis with an IC₅₀ of 350 nM .

HY-B0135R

Furosemide (Standard) 5+ Cited Publications	Reference Standards NKCC GABA Receptor	Metabolic Disease Cancer
Furosemide (Standard) is the analytical standard of Furosemide. This product is intended for research and analytical applications. Furosemide is a potent and orally active inhibitor of Na ⁺/K ⁺/2Cl ^- (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide is also a GABA_A receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .

HY-10019A

Varenicline dihydrochloride CP 526555 dihydrochloride	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-W010934

3β,5α,6β-Trihydroxycholestane	Biochemical Assay Reagents	Others
3β,5α,6β-Trihydroxycholestane is a steroid that occurs naturally in the body and is also found in certain foods. It belongs to a class of compounds known as cholestanes, which are closely related to the better known cholesterol. This particular compound is formed from cholesterol through a series of enzymatic reactions in the liver and other organs. It has been studied for its potential health benefits, including its ability to reduce inflammation and oxidative stress in the body. Some research suggests that it may also play a role in regulating blood sugar levels and improving insulin sensitivity. Despite these potential benefits, 3β,5α,6β-Trihydroxycholestane is not widely used as a supplement or medicine due to its relatively low content, focus on natural resources and limited research. However, researchers continue to investigate its potential uses and effects on human health.

HY-149483

CVN417	nAChR	Neurological Disease
CVN417 is an orally active α6 subunit-containing nAChR antagonist, modulating phasic dopaminergic neurotransmission in an impulse-dependent manner. CVN417 inhibits Ca(2+) effluents mediated by nAChR subunits with IC₅₀s of 0.086 μM (α6), 2.56 μM (α3) and 0.657 μM (α4), respectively. CVN417 attenuates resting tremor in Rodent models, displays the potential to improve movement dysfunction, in conditions such as Parkinson's disease .

HY-16031

AFP464 free base NSC710464 free base	Aryl Hydrocarbon Receptor Integrin Drug Intermediate DNA/RNA Synthesis	Cancer
AFP464 (NSC710464) free base is a prodrug of Aminoflavone (HY-132974) and an agonist of the aryl hydrocarbon receptor (AhR). AFP464 free base downregulates the expression of α6-integrin (α6-integrin), inhibits breast tumor growth, reduces the population of tumor-initiating cells, disrupts mammosphere structure, induces the formation of mucin lake clusters, triggers DNA damage, and exerts antiproliferative activity. AFP464 free base is rapidly converted to Aminoflavone by nonspecific esterases in plasma and cell culture media. AFP464 free base is applicable to research related to breast cancer .

HY-W002112S

(±)-Nornicotine-d4 Nornicotine-d₄	nAChR Isotope-Labeled Compounds Endogenous Metabolite Drug Metabolite β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-W009009

L-838417	GABA Receptor	Neurological Disease
L-838417 is a selective partial agonist at the α2, α3 and α5 subtypes of the GABA_A receptor and an antagonist at the α1, with binding K_i values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2 and α6β3γ2. L-838417 has anti-anxiety activity .

HY-W342092

1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril	Biochemical Assay Reagents Endogenous Metabolite
1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril is a chemical agent that has the property of inhibiting enzyme activity in organisms. 1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril is used as a potential anti-tumor agent in compound development. 1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril has the effect of regulating cell signaling pathways and can be used to study cell biology. 1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril is considered to be a potent compound that can exert biological activity under specific conditions.

HY-N15777

Tauro-3α,6α,7α,12α-tetrahydroxy bile acid sodium	Biochemical Assay Reagents	Metabolic Disease
Tauro-3α,6α,7α,12α-tetrahydroxy bile acid sodium is a type of bile acid, belonging to biomolecules synthesized by the liver using cholesterol as a raw material. Bile acids play a critical role in the digestion and absorption of lipids in the small intestine .

HY-16031B

AFP464 dihydrochloride NSC710464 dihydrochloride	Aryl Hydrocarbon Receptor Integrin Drug Intermediate DNA/RNA Synthesis	Cancer
AFP464 (NSC710464) dihydrochloride is a prodrug of Aminoflavone (HY-132974) and an agonist of the aryl hydrocarbon receptor (AhR). AFP464 dihydrochloride downregulates the expression of α6-integrin (α6-integrin), inhibits breast tumor growth, reduces the population of tumor-initiating cells, disrupts mammosphere structure, induces the formation of mucin lake clusters, triggers DNA damage, and exerts antiproliferative activity. AFP464 dihydrochloride is rapidly converted to Aminoflavone by nonspecific esterases in plasma and cell culture media. AFP464 dihydrochloride is applicable to research related to breast cancer .

HY-152170

bPiDI 1 Publications Verification	nAChR	Neurological Disease
bPiDI is a novel selective *α6β2* nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-120837

PZ-II-029	GABA Receptor	Neurological Disease
PZ-II-029 is a GABAA positive allosteric modulator that selectively binds with high affinity to *α6β3γ2*. PZ-II-029 shows anti-migraine effects .

HY-N10639

(1α,2α,6β,8α,9α)-1,2,6,8,12-Pentakis(acetyloxy)-9-(benzoyloxy)dihydro-β-agarofuran	Others	Others
(1α,2α,6β,8α,9α)-1,2,6,8,12-Pentakis(acetyloxy)-9-(benzoyloxy)dihydro-β-agarofuran is a sesquiterpene polyol ester. (1α,2α,6β,8α,9α)-1,2,6,8,12-Pentakis(acetyloxy)-9-(benzoyloxy)dihydro-β-agarofuran can be used for the research of various biochemical .

HY-124110

TC299423	nAChR	Neurological Disease
TC299423 is an orally active, brain-penetrant, selective and potent agonist for α6β2 ^? and α4β2 ^? nicotinic acetylcholine receptors (nAChRs) with anxiolytic and antinociceptive properties. TC299423 acts primarily through α6β2 ^? nAChRs that are implicated in the anxiolytic effects of nicotine. TC299423 elicits reward-related behavior mediated through α6β2 ^? nAChRs in hypersensitive α6L90’S mice. TC299423 elicits dopamine release and dose not suppress nicotine self-administration in rats. TC299423 is proming for rasearch of addiction and Parkinson’s disease .

HY-151129

nAChR-IN-1	nAChR	Neurological Disease
nAChR-IN-1 (2,2,6,6-Tetramethylpiperidin-4-yl heptanoate) is a tetramethylpiperidine heptanoate, a selective nicotinic acetylcholine receptor (nAChR) inhibitor that inhibits nAChRs lacking α5, α6, or β3 subunits. nAChR-IN-1 has the effect of preventing nerve disorder, can be used for nicotinic acetylcholine receptor dysfunction or neurological disorders research .

HY-138879B

CP-601932 (1S,5R)-CP-601927	nAChR	Neurological Disease
CP-601932 ((1S,5R)-CP-601927) is a high-affinity partial agonist at α3β4 nAChR (K_i=21 nM; EC₅₀=~ 3 μM). CP-601932 has the same high-binding affinity at α4β2 nAChR (K_i=21 nM) and an order of magnitude lower affinity for α6 and α7 nAChR subtypes. CP-601932 selectively decreases ethanol but not sucrose consumption and operant self-administration following long-term exposure. CP-601932 can penetrate the CNS .

HY-134902

UDP-6-azido-6-Deoxy-D-Glc UDP-α-6N3-glucose; 6-Azidoglucose-UDP	Nucleoside Antimetabolite/Analog	Others
UDP-6-azido-6-Deoxy-D-Glc (UDP-α-6N3-glucose) is a nucleotide sugar. UDP-α-6 N3-glucoside can be used in the selective labeling of 5-hmC in genomic DNA .

HY-162518

Eg5-IN-3	Kinesin Microtubule/Tubulin	Cancer
Eg5-IN-3 (5) is an Eg5 inhibitor that targets the novel allosteric pocket (α4/α6/L11). Eg5-IN-3 (5) causes tubulin assembly distortion with irregular morphology, resulting in a typical mitotic arrest similar to Monastrol (HY-101071A) .

HY-107669

nAChR-IN-1 hydrochloride	nAChR	Neurological Disease
nAChR-IN-1 (hydrochloride) is a tetramethylpiperidine heptanoate, a selective nicotinic acetylcholine receptor (nAChR) inhibitor that inhibits nAChRs lacking α5, α6, or β3 subunits. nAChR-IN-1 has the effect of preventing nerve disorder, can be used for nicotinic acetylcholine receptor dysfunction or neurological disorders research .

HY-107674

bPiDDB	nAChR	Neurological Disease
bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC₅₀=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-10021R

Varenicline Tartrate (Standard) CP 526555-18 (Standard)	Reference Standards nAChR ERK p38 MAPK	Others Neurological Disease
Varenicline (Tartrate) (Standard) is the analytical standard of Varenicline (Tartrate). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-103496

U-90042	GABA Receptor	Neurological Disease
U-90042 is a gamma-aminobutyric acidA receptor agonist of α1, α3 and α6 subtypes with K_i values of 7.8 nM, 9.5 nM and 11.0 nM, respectively. U-90042 suppresses locomotor activity and impairs rotarod performance in mice. U-90042 produces sedation and ataxia and prolongs sleeping time in mice, rats and monkeys. U-90042 can be used as a sedative and hypnotic agent .

HY-W002112R

(±)-Nornicotine (Standard) Nornicotine (Standard)	Reference Standards Endogenous Metabolite Drug Metabolite nAChR β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine (HY-W002112). This product is intended for research and analytical applications. (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-W002112S1

(±)-Nornicotine-d7 Nornicotine-d₇	Isotope-Labeled Compounds Endogenous Metabolite Drug Metabolite nAChR β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-A0009R

Galanthamine hydrobromide (Standard) Galantamine hydrobromide (Standard)	nAChR Cholinesterase (ChE) Reference Standards	Neurological Disease
Galanthamine (hydrobromide) (Standard) is the analytical standard of Galanthamine (hydrobromide). This product is intended for research and analytical applications. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-B0135AR

Furosemide sodium (Standard)	NKCC GABA Receptor Reference Standards	Cardiovascular Disease Metabolic Disease Cancer
Furosemide (sodium) (Standard) is the analytical standard of Furosemide (sodium). This product is intended for research and analytical applications. Furosemide sodium is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .

HY-14565

Pozanicline ABT-089	nAChR	Neurological Disease
Pozanicline (ABT-089) selectively activate neuronal nicotinic acetylcholine receptor (nAChR) subtypes, is a novel cholinergic agent that is a partial agonist at α4β2* nAChRs (K_i=16 nM) and shows high selectivity for α6β2* and α4α5β2 nAChR subtypes, the binding affinity (K_i, rat) for Pozanicline to [ ³H] cytisine sites is 16.7 nM. Pozanicline reverses nicotine withdrawal-induced cognitive deficits, may be an effective component of novel therapeutic strategies for nicotine addiction .

HY-169330

3β,5α,6β-Trihydroxycholanic acid	Drug Metabolite	Neurological Disease Metabolic Disease
3β,5α,6β-Trihydroxycholanic acid is a metabolite of 3β,5α,6β-Trihydroxycholestane (HY-W010934). 3β,5α,6β-Trihydroxycholanic acid can be used in research related to neurodegenerative diseases associated with lysosomal dysfunction .

HY-W726076

3α,6α-Mannopentaose	Biochemical Assay Reagents	Others
3α,6α-Mannopentaose is a class of biochemical reagents used in glycobiology research. Glycobiology studies the structure, synthesis, biology, and evolution of sugars. It involves carbohydrate chemistry, enzymology of glycan formation and degradation, protein-glycan recognition, and the role of glycans in biological systems. This field is closely related to basic research, biomedicine, and biotechnology .

HY-N1202

Sitostanetriol Sitostane-3β,5α,6β-triol	Others	Others
Sitostanetriol (Sitostane-3β,5α,6β-triol) is a steroid isolated from Casearia membranacea (Flacourtiaceae) .

HY-N15854

3α,6β,7α,12α-Tetrahydroxy bile acid	Biochemical Assay Reagents	Others
3α,6β,7α,12α-Tetrahydroxy bile acid is a tetrahydroxy derivative of bile acids.

HY-N15788

3α,6α,7α,12α-Tetrahydroxy bile acid	Endogenous Metabolite	Others
3α,6α,7α,12α-Tetrahydroxy bile acid is a hydrophilic tetrahydroxy derivative of bile acids.

HY-146767S

(3β,5α,6β)-3,5,6-Trihydroxycholan-24-oic acid-d4	Isotope-Labeled Compounds	Others
(3β,5α,6β)-3,5,6-Trihydroxycholan-24-oic acid-d₄ is deuterium labeled (3β,5α,6β)-3,5,6-Trihydroxycholan-24-oic acid.

HY-N9175

4α,6α-Dihydroxyeudesm-11(13)-en-12,8β-olide	Others	Others
4α,6α-Dihydroxyeudesm-11(13)-en-12,8β-olide is a Sesquiterpenoids product that can be isolated from the herbs of Chloranthus elatior .

Cat. No.	Product Name	Type

HY-133971

Cholesterol 5α,6α-epoxide

5α,6α-Epoxycholesterol

Biochemical Assay Reagents

Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.

HY-W010934

3β,5α,6β-Trihydroxycholestane

Biochemical Assay Reagents

3β,5α,6β-Trihydroxycholestane is a steroid that occurs naturally in the body and is also found in certain foods. It belongs to a class of compounds known as cholestanes, which are closely related to the better known cholesterol. This particular compound is formed from cholesterol through a series of enzymatic reactions in the liver and other organs. It has been studied for its potential health benefits, including its ability to reduce inflammation and oxidative stress in the body. Some research suggests that it may also play a role in regulating blood sugar levels and improving insulin sensitivity. Despite these potential benefits, 3β,5α,6β-Trihydroxycholestane is not widely used as a supplement or medicine due to its relatively low content, focus on natural resources and limited research. However, researchers continue to investigate its potential uses and effects on human health.

HY-W726076

3α,6α-Mannopentaose

Biochemical Assay Reagents

3α,6α-Mannopentaose is a class of biochemical reagents used in glycobiology research. Glycobiology studies the structure, synthesis, biology, and evolution of sugars. It involves carbohydrate chemistry, enzymology of glycan formation and degradation, protein-glycan recognition, and the role of glycans in biological systems. This field is closely related to basic research, biomedicine, and biotechnology .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W002112

(±)-Nornicotine Nornicotine	Structural Classification Alkaloids Pyrrole Alkaloids Neurological Disease Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-A0009

Galanthamine hydrobromide 10+ Cited Publications Galantamine hydrobromide	Alkaloids Other Alkaloids Plants Amaryllidaceae	Cholinesterase (ChE) nAChR
Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-N15777

Tauro-3α,6α,7α,12α-tetrahydroxy bile acid sodium	Structural Classification Lipid	Biochemical Assay Reagents
Tauro-3α,6α,7α,12α-tetrahydroxy bile acid sodium is a type of bile acid, belonging to biomolecules synthesized by the liver using cholesterol as a raw material. Bile acids play a critical role in the digestion and absorption of lipids in the small intestine .

HY-W002112R

(±)-Nornicotine (Standard) Nornicotine (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Pyridine Alkaloids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine (HY-W002112). This product is intended for research and analytical applications. (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-A0009R

Galanthamine hydrobromide (Standard) Galantamine hydrobromide (Standard)	Structural Classification Alkaloids Other Alkaloids Plants Amaryllidaceae Source Classification	nAChR Cholinesterase (ChE) Reference Standards
Galanthamine (hydrobromide) (Standard) is the analytical standard of Galanthamine (hydrobromide). This product is intended for research and analytical applications. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-N1202

Sitostanetriol Sitostane-3β,5α,6β-triol	Triterpenes Clausena anisata (Willd.) Hook.f. ex Benth. Terpenoids Plants Salicaceae Source Classification	Others
Sitostanetriol (Sitostane-3β,5α,6β-triol) is a steroid isolated from Casearia membranacea (Flacourtiaceae) .

HY-N15854

3α,6β,7α,12α-Tetrahydroxy bile acid	Lipid	Biochemical Assay Reagents
3α,6β,7α,12α-Tetrahydroxy bile acid is a tetrahydroxy derivative of bile acids.

HY-N15788

3α,6α,7α,12α-Tetrahydroxy bile acid	Lipid	Endogenous Metabolite
3α,6α,7α,12α-Tetrahydroxy bile acid is a hydrophilic tetrahydroxy derivative of bile acids.

HY-N9175

4α,6α-Dihydroxyeudesm-11(13)-en-12,8β-olide	Terpenoids Sesquiterpenes Chloranthus erectus (Buchanan-Hamilton) Verdcourt Chloranthaceae Plants Source Classification	Others
4α,6α-Dihydroxyeudesm-11(13)-en-12,8β-olide is a Sesquiterpenoids product that can be isolated from the herbs of Chloranthus elatior .

HY-N15534A

5α,6β-Dihydroxy-3β-(β-D-glucopyranosyloxy)-7E-megastigmen-9-one	Piperaceae Piper crocatum Ruiz & Pav. Plants Saccharides Monosaccharides Source Classification	Endogenous Metabolite
5α,6β-Dihydroxy-3β-(β-D-glucopyranosyloxy)-7E-megastigmen-9-one (Compound 18) is a megastigmane glucoside isomer. 5α,6β-Dihydroxy-3β-(β-D-glucopyranosyloxy)-7E-megastigmen-9-one can be isolated from the Piper genus and Piperaceae family .

HY-N12135

15α-Hydroxy-20-oxo-6,7-seco-ent-kaur-16-en-1,7α(6,11α)-diolide	Senegalia pennata (L.) Maslin Terpenoids Labiatae Diterpenoids Plants Source Classification	Others
15α-Hydroxy-20-oxo-6,7-seco-ent-kaur-16-en-1,7α(6,11α)-diolide (compound 2) is an enantio-kaurene diterpenoid (ent -kaurene diterpenoid), which can be isolated from Rubescens rubescens. 15α-Hydroxy-20-oxo-6,7-seco-ent-kaur-16-en-1,7α(6,11α)-diolide has cellular activity against EC-1, U87, A549, MCF-7 and HeLa cell lines Toxicity, IC₅₀s are 37.69 μM, 79.362 μM, 80.07 μM, 197.35 μM, 462.13 μM, and 180.09 μM respectively .

HY-N19578

5α,6α-Epoxystigmasterol	Structural Classification Tetracyclic Triterpenoids Terpenoids Nigella sativa L. Ranunculaceae Plants Source Classification	Drug Intermediate
5α,6α-Epoxystigmasterol is a sterol epoxide. 5α,6α-Epoxystigmasterol serves as a precursor of brassinosteroidal compounds .

HY-N15891

Glyco-3ß,5α,6ß -trihydroxycholanoic acid (NPCBA2)	Lipid	Endogenous Metabolite
Glyco-3ß,5α,6ß -trihydroxycholanoic acid (NPCBA2) is a bile acid which accumulates preferentially in Niemann-Pick C (NPC) patients. Glyco-3ß,5α,6ß -trihydroxycholanoic acid is a biomarker for the early diagnosis of Niemann-Pick C disease .

HY-N15768

Tauro-3β,5α,6β-trihydroxycholanoic acid sodium	Lipid	Biochemical Assay Reagents
Tauro-3β,5α,6β-trihydroxycholanoic acid sodium is a bile acid (BA) suitable to investigate BAs and their relatives’ behavior and correlation with liver, gallbladder, and bile ducts diseases.

HY-N1810

Ditigloylteloidine 3α,6β-Ditigloyloxytropan-7β-ol	Alkaloids Solanaceae Plants Datura metel Linn. Source Classification	Others
Ditigloylteloidine (3α,6β-Ditigloyloxytropan-7β-ol) is a Sesquiterpenoids product that can be isolated from the herbs of Eupatorium chinense var. tozanense. .

HY-N17103

5α,6α-Epoxy-3β-hydroxymegastigm-7-en-9-one	Structural Classification Ketones, Aldehydes, Acids Amaranthaceae Plants Beta vulgaris var. cicla L. Source Classification	Drug Derivative
5α,6α-Epoxy-3β-hydroxymegastigm-7-en-9-one is a natural sesquiterpene.

HY-N17232

5α,6α-Epoxyergosta-8,22-diene-3β,7α-diol	Structural Classification Microorganisms Steroids Source Classification	Drug Derivative
5α,6α-Epoxyergosta-8,22-diene-3β,7α-diol is a natural steroid.

HY-N17230

5α,6α-Epoxyergosta-8(14),22-diene-3β,7α-diol	Structural Classification Microorganisms Steroids Source Classification	Drug Derivative
5α,6α-Epoxyergosta-8(14),22-diene-3β,7α-diol is a natural steroid.

HY-N17400

(22E,24R)-23-Methylergosta-7,22-diene-3β,5α,6β-triol	Structural Classification Tetracyclic Triterpenoids Microorganisms Terpenoids Steroids Source Classification	Others
(22E,24R)-23-Methylergosta-7,22-diene-3β,5α,6β-triol (Compound 7) is an Ergosteroid. (22E,24R)-23-Methylergosta-7,22-diene-3β,5α,6β-triol can be isolated from Penicillium herquei. (22E,24R)-23-Methylergosta-7,22-diene-3β,5α,6β-triol exhibits no obvious inhibitory activities against NO production induced by LPS .

HY-N10032

(3β,5α,6α,16β)-8,14-Didehydrocevane-3,6,16,20-tetrol	Structural Classification Alkaloids Liliaceae Other Alkaloids Fritillaria ussuriensis Maxim. Plants Source Classification	Cholinesterase (ChE)
(3β,5α,6α,16β)-8,14-Didehydrocevane-3,6,16,20-tetrol (compound 3) is an inhibitor targeting acetylcholinesterase (AChE). At a concentration of 100 μg/mL, (3β,5α,6α,16β)-8,14-Didehydrocevane-3,6,16,20-tetrol exhibits an in vitro inhibition rate of 12% against AChE .

HY-N17311

(22E,24R)-5α,6α-Epoxyergosta-8,22-diene-3β,7β-diol	Structural Classification Microorganisms Steroids Source Classification	Others
(22E,24R)-5α,6α-Epoxyergosta-8,22-diene-3β,7β-diol (Compound 3) is an ergosterol. (22E,24R)-5α,6α-Epoxyergosta-8,22-diene-3β,7β-diol can be isolated from A. subjunquillea. (22E,24R)-5α,6α-Epoxyergosta-8,22-diene-3β,7β-diol can be used in the research of non-small cell lung cancer, ovarian cancer, melanoma, and colon cancer .

HY-N9877

22E-7α-Methoxy-5α,6α-epoxyergosta-8(14),22-dien-3β-ol	Structural Classification Pteridaceae Acrostichum speciosum Willd. Plants Steroids Source Classification	Drug Derivative
22E-7α-Methoxy-5α,6α-epoxyergosta-8(14),22-dien-3β-ol is a natural steroid.

HY-N17426

(3β,5α,6α,22E)-Ergosta-7,22-diene-3,5,6-triol	Structural Classification Natural Products Microorganisms Hymenogastraceae Plants Source Classification Gymnopilus spectabilis	Drug Derivative
(3β,5α,6α,22E)-Ergosta-7,22-diene-3,5,6-triol is a natural product that can be found in animal bile.

HY-N17401

(22E,24R)-Ergosta-7,9(11),22-triene-3β,5α,6β-triol	Structural Classification Tetracyclic Triterpenoids Microorganisms Terpenoids Steroids Source Classification	Drug Derivative
(22E,24R)-Ergosta-7,9(11),22-triene-3β,5α,6β-triol is a natural product that can be found in Claviceps purpurea.

HY-N17427

(R)-(22E,24R)-Ergosta-7,9(11),22-triene-3β,5α,6β-triol	Structural Classification Natural Products Microorganisms Source Classification	Others
(R)-(22E,24R)-Ergosta-7,9(11),22-triene-3β,5α,6β-triol (compound 3) is a sterol that can be found in of Grifola frondosa .

Species:	Human (11)
Tag:	His (9) Avi (2) Myc (1) GST (1) Fc (1) Flag (2)
Source:	HEK293 (9) Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704251

	*Integrin alpha 6* beta 1 Protein, Human (HEK293, His)** α6β1; Integrin alpha 6 beta 1; ITGA6&ITGB1; Integrin alpha 6 β 1	Human	HEK293

HY-P700764

	*Integrin alpha 6* beta 1 Protein, Human (HEK293, His-Avi)** α6β1; Integrin alpha 6 beta 1; ITGA6&ITGB1; Integrin alpha 6 β 1	Human	HEK293
	Integrin alpha 6 beta 1 Protein, Human (HEK293, His-Avi) is the recombinant human-derived Integrin alpha 6 beta 1 protein, expressed by HEK293, with C-Avi, C-His labeled tag., has molecular weight of 110-130 kDa.

HY-P702621

	*Integrin alpha 6* beta 1 Protein, Human (Biotinylated, HEK293, His, Avi)** α6β1; Integrin alpha 6 beta 1; ITGA6&ITGB1; Integrin alpha 6 β 1	Human	HEK293
	Integrin alpha 6 beta 1 Protein, Human (Biotinylated, HEK293, His, Avi) is the recombinant human-derived Integrin alpha 6 beta 1, expressed by HEK293 , with C-Avi, C-His labeled tag. ,

HY-P704723

	*Integrin alpha 6* beta 4 Protein, Human (HEK293, His)** Integrin alpha 6 beta 4; ITGA6&ITGB4	Human	HEK293

HY-P73870

	*Integrin alpha 6* beta 4 Protein, Human (HEK293, Flag-His)** 1 Publications Verification Integrin alpha 6 beta 4; ITGA6; ITGB4	Human	HEK293
	Integrin alpha 6 beta 4 Protein, Human (HEK293, Flag-His) is the recombinant human-derived Integrin alpha 6 beta 4 protein, expressed by HEK293, with C-His, C-Flag labeled tag., has molecular weight of ~196 kDa.

HY-P73871

	*Integrin alpha 6* beta 1 Protein, Human (HEK293, Flag-His)** CD49f; Integrin alpha 6 beta 1; ITGA6B; VLA-6	Human	HEK293
	Integrin alpha 6 beta 1 Protein, Human (HEK293, Flag-His) is the recombinant human-derived Integrin alpha 6 beta 1 protein, expressed by HEK293, with C-His, C-Flag labeled tag., has molecular weight of ~110 & 130 kDa, respectively.

HY-P72244

	*IFN-alpha 6/IFNA6 Protein, Human (His-Myc)* IFNA6Interferon alpha-6; IFN-alpha-6; Interferon alpha-54; Interferon alpha-K; LeIF K	Human	E. coli
	IFN-alpha 6 (IFNA6), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 6/IFNA6 Protein, Human (His-Myc) contains 169 a.a. (S21-E189), produced in E. coli cells with a N-terminal His-tag and a C-terminal Myc-tag.

HY-P72614

	*IFN-alpha 6/IFNA6 Protein, Human (HEK293, His)* Interferon Alpha-6; IFN-Alpha-6; Interferon Alpha-54; Interferon Alpha-K; LeIF K; IFNA6	Human	HEK293
	IFN-alpha 6 (IFNA6), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 6/IFNA6 Protein, Human (HEK293, His) contains 169 a.a. (S21-E189), produced in HEK293 cells with a C-terminal His-tag.

HY-P702651

	RPS6KA6 Protein, Human (Active, sf9, GST) RPS6KA6; ribosomal protein S6 kinase, 90kDa, polypeptide 6; ribosomal protein S6 kinase, 90kD, polypeptide 6; ribosomal protein S6 kinase alpha-6; RSK4; RSK-4; p90RSK6; p90-RSK 6; S6K-alpha 6; S6K-alpha-6; ribosomal S6 kinase 4; 90 kDa ribosomal protein S6 kinase 6; PP90RSK4	Human	Sf9 insect cells
	RSK4 (ribosomal S6 kinase 4) is a serine/threonine protein kinase that is constitutively active and does not require the presence of growth factors to function. It is involved in cell signaling pathways related to cell growth arrest, especially those mediated by p53/TP53 proteins. RPS6KA6 Protein, Human (sf9, GST) is the recombinant human-derived RPS6KA6, expressed by Sf9 insect cells, with GST labeled tag.

HY-P76457

	IFN-alpha 10/IFNA10 Protein, Human (HEK293, His) Interferon alpha-10; Interferon alpha-6L; Interferon alpha-C; LeIF C	Human	HEK293
	IFN-alpha 10 (IFNA10), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 10/IFNA10 Protein, Human (HEK293, His) contains 189 a.a. (M1-D189), produced in HEK293 cells with a C-terminal His-tag.

HY-P76456

	IFN-alpha 10/IFNA10 Protein, Human (HEK293, Fc) Interferon alpha-10; Interferon alpha-6L; Interferon alpha-C; LeIF C	Human	HEK293
	IFN-alpha 10 (IFNA10), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 10/IFNA10 Protein, Human (HEK293, Fc) contains 166 a.a. (C24-D189), produced in HEK293 cells with a N-terminal hFc-tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0135S

Furosemide-d5

Furosemide-d₅ is the deuterium labeled Furosemide. Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl-?(NKCC) cotransporter, NKCC1 and NKCC2 .?Furosemide is also a GABAA?receptors antagonist and displays 100-fold selectivity for?α6-containing receptors than?α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .

HY-15831

L-838417-d9
L-838417-d₉ is the deuterium labeled L-838417 (HY-W009009). L-838417 is a selective partial agonist at the α2, α3 and α5 subtypes of the GABA_A receptor and an antagonist at the α1, with binding K_i values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2 and α6β3γ2. L-838417 has anti-anxiety activity .

HY-W002112S

(±)-Nornicotine-d4

(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-W002112S1

(±)-Nornicotine-d7

(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-146767S

(3β,5α,6β)-3,5,6-Trihydroxycholan-24-oic acid-d4
(3β,5α,6β)-3,5,6-Trihydroxycholan-24-oic acid-d₄ is deuterium labeled (3β,5α,6β)-3,5,6-Trihydroxycholan-24-oic acid.

HY-150857S

*Thymine-α,α,α,6-d4 Glycol (mixture of diastereomers)-d4*
Thymine-α,α,α,6-d₄ Glycol (mixture of diastereomers)-d₄ is the deuterium labeled Thymine-α,α,α,6-d4 Glycol (mixture of diastereomers) .

HY-10020S

Varenicline-15N3 hydrochloride

Varenicline-15N3 Hydrochloride (CP 526555-15N3 Hydrochloride) is the ¹⁵N labeled isotope of Varenicline hydrochloride (HY-10020). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-A0009S

Galanthamine-d3 hydrobromide

Galanthamine-d₃ (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-10019S2

Varenicline-13C15N

Varenicline- ¹³C ¹⁵N (CP 526555- ¹³C ¹⁵N) is ¹³C and ¹⁵N labeled Varenicline. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019S1

Varenicline-15N,13C,d2

Varenicline- ¹⁵N, ¹³C,d₂ is ¹⁵N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-133971S

Cholesterol-5α,6α-epoxide-d7
Cholesterol-5α,6α-epoxide-d₇ is deuterium labeled Cholesterol-5α,6α-epoxide.

HY-W010934S

3β,5α,6β-Trihydroxycholestane-d7
3β,5α,6β-Trihydroxycholestane-d₇ is the deuterium labeled 3β,5α,6β-Trihydroxycholestane .

Host:	Mouse (3) Rabbit (6)
Reactivity:	Human (9) Bovine (1) Rat (4) Mouse (4) Dog (1) Pig (1)
Application:	IHC-P (1) ICC/IF (5) WB (9)
Isotype:	IgG (6) IgG1 (2)
Conjugation:	Non-conjugated (9) Biotin (1)
Clonality:	Monoclonal (6) Recombinant (4)
Modification:	Phosphorylated (1) Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82004

	*Proteasome alpha 6* Antibody (YA1749)** proteasome subunit alpha 6; IOTA; p27K; PROS27	WB, ICC/IF	Human, Mouse, Rat
	Proteasome alpha 6 Antibody (YA1749) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Proteasome alpha 6.

HY-P82004A

	*Proteasome alpha 6* Antibody (YA1749)(PBS only)** proteasome subunit alpha 6; IOTA; p27K; PROS27	WB, ICC/IF	Human, Mouse, Rat
	Proteasome alpha 6 Antibody (YA1749) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Proteasome alpha 6.

HY-P85440

	*Integrin alpha 6* Antibody (YA5132)** ITGA6; Integrin alpha-6; CD49 antigen-like family member F; VLA-6; CD antigen CD49f	WB, ICC/IF	Human, Mouse, Rat, Bovine, Dog, Pig
	Integrin alpha 6 Antibody (YA5132) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Integrin alpha 6.

HY-P83275

	*Integrin alpha 6* Antibody (YA3020)** ITGA6; CD49 antigen-like family member F; VLA-6; CD49f	WB, IHC-P	Human, Mouse, Rat
	Integrin alpha 6 Antibody (YA3020) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Integrin alpha 6.

HY-P80851

	Phospho-RSK4 (Ser232) Antibody (YA155) RPS6KA6; RSK4; Ribosomal protein S6 kinase alpha-6; S6K-alpha-6; 90 kDa ribosomal protein S6 kinase 6; p90-RSK 6; p90RSK6; Ribosomal S6 kinase 4; RSK-4; pp90RSK4	WB, ICC/IF	Human
	Phospho-RSK4 (Ser232) Antibody (YA155) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-RSK4 (Ser232).

HY-P80890

	S100A6 Antibody (YA674) S100 alpha6; Protein S100-A6; Calcyclin; MLN 4; PRA; CACY; CABP; 5B10	WB	Human
	S100A6 Antibody (YA674) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to S100A6.

HY-P80851A

	Phospho-RSK4 (Ser232) Antibody (YA155)(PBS only) RPS6KA6; RSK4; Ribosomal protein S6 kinase alpha-6; S6K-alpha-6; 90 kDa ribosomal protein S6 kinase 6; p90-RSK 6; p90RSK6; Ribosomal S6 kinase 4; RSK-4; pp90RSK4	WB, ICC/IF	Human
	Phospho-RSK4 (Ser232) Antibody (YA155) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-RSK4 (Ser232).

HY-P80890A

	S100A6 Antibody (YA674)(PBS only) S100 alpha6; Protein S100-A6; Calcyclin; MLN 4; PRA; CACY; CABP; 5B10	WB	Human
	S100A6 Antibody (YA674) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to S100A6.

HY-P86829

	CXCL1/GRO alpha Antibody (YA6522) C-X-C motif chemokine 1 antibody; Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) antibody; chemokine (C-X-C motif) ligand 1 antibody; CINC-1 antibody; CXCL1 antibody; Cytokine-induced neutrophil chemoattractant 1 antibody; Fibroblast secretory protein antibody; Fsp antibody; Gro 1 antibody; Gro A antibody; C-X-C motif chemokine 1 antibody; Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) antibody; chemokine (C-X-C motif) ligand 1 antibody; CINC-1 antibody; CXCL1 antibody; Cytokine-induced neutrophil chemoattractant 1 antibody; Fibroblast secretory protein antibody; Fsp antibody; Gro 1 antibody; Gro A antibody; Gro antibody; GRO protein, alpha antibody; GRO-alpha(1-73) antibody; GRO-alpha(6-73) antibody; Gro1 antibody; GRO1 oncogene (melanoma growth stimulating activity, alpha) antibody; GRO1 oncogene (melanoma growth-stimulating activity) antibody; Gro1 oncogene antibody; GROa antibody; GROA_HUMAN antibody; Growth-regulated alpha protein antibody; KC antibody; KC chemokine, mouse, homolog of antibody; melanoma growth stimulatory activity alpha antibody; Melanoma growth stimulatory activity antibody; Melanoma growth stimulatory activity, alpha antibody; MGSA alpha antibody; MGSA antibody; MGSA-a antibody; N51 antibody; NAP-3 antibody; NAP3 antibody; Neutrophil-activating protein 3 antibody; Platelet-derived growth factor-inducible protein KC antibody; Scyb 1 antibody; Scyb1 antibody; Secretory protein N51 antibody; Small inducible cytokine subfamily B, member 1 antibody;	WB	Human
	CXCL1/GRO alpha Antibody (YA6522) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CXCL1/GRO alpha.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-133971

Cholesterol 5α,6α-epoxide 5α,6α-Epoxycholesterol		Cholesterol
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.

HY-128671

6-Thioinosine 6TI; 6-Mercaptopurine riboside		Nucleoside Analogs Inosine
6-Thioinosine (6TI) is a purine antimetabolite and an anti-adipogenic agent. 6-Thioinosine reduces the mRNA levels of PPARγ and C/EBPα and downregulates the mRNA levels of PPARγ target genes (LPL, CD36, aP2, and LXRα). 6-Thioinosine exerts its anti-adipogenic effects by downregulating PPARγ through JNK-dependent iNOS upregulation. 6-Thioinosine can be used to study adipocyte dysfunction .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

α6

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products